Expanding Business Scale and Earnings Through M&A
First written in FY2016. 19 of 29 entries say "Advanced", first in FY2017. Latest entry: FY2026.
91 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「May 2025: To strengthen the Group's procurement capabilities, the company established ミウル・ヘルスケア㈱ (head office: Chuo-ku, Tokyo; now a consolidated subsidiary) as a joint venture with 伊藤忠リーテイルリンク㈱, and commenced operations in August 2025.」
As a specific development under its policy of pursuing alliances in addition to M&A, the company established a joint venture to strengthen procurement capabilities and commenced operations. - FY2024RestatedAnnual report
「To maintain growth in response to changes in the industry environment and meet the increasingly diverse needs of healthcare providers, the Group aims to expand its corporate scale through M&A with companies rooted in their respective local communities as a medium- to long-term management strategy.」
The company continues to pursue the expansion of its corporate scale and business base through M&A with companies rooted in their local communities as a medium- to long-term strategy. - FY2024-Q3AdvancedAnnual report
「At a meeting of the board of directors held on 21 February 2024, the company resolved to acquire 65% of the issued shares of マコト医科精機株式会社 (hereinafter, "マコト医科精機") and make it a subsidiary, entered into a share transfer agreement on the same date, and acquired the shares effective 1 March 2024. On 30 April 2024, the company and マコト医科精機 conducted a share exchange under which the company became the wholly owning parent company and マコト医科精機 became the wholly owned subsidiary, making マコト医科精機 a wholly owned subsidiary of the company.」
Under its policy of continuing M&A, the company acquired 65% of マコト医科精機 on 1 March 2024 and made it a wholly owned subsidiary through a share exchange on 30 April 2024. - FY2023AdvancedAnnual report
「The acquisition of this business, with ㈱オーソエッジジャパン as the acquiring company, was completed effective 1 July 2023.」
Under its policy of expanding its business base through M&A and business acquisitions, the company completed the acquisition of 田中医科器械製作所's medical equipment and other purchasing and sales business effective 1 July 2023. - FY2023-Q3AdvancedAnnual report
「The company determined that acquiring the business of 田中医科 involving the purchase and sale of medical equipment and other products would increase its market share in Chiba Prefecture and enable the two companies to generate synergies by combining their sales expertise and other capabilities.」
Under its M&A and business expansion policy, the acquisition of the medical equipment and other purchasing and sales business of 田中医科器械製作所 progressed through the basic agreement, definitive agreement and change in the acquiring company. - FY2023-Q1AdvancedAnnual report
「At a meeting of the board of directors held on 29 August 2022, the company resolved that its consolidated subsidiary アクティブメディカル (hereinafter, "アクティブメディカル") would acquire all shares of ノアインターナショナル株式会社 (hereinafter, "ノアインターナショナル") and make it a subsidiary, thereby making it an indirect subsidiary of the company, and acquired the shares effective 4 October 2022.」
Under its policy of continuing M&A, the company acquired all shares of ノアインターナショナル through アクティブメディカル and made it a subsidiary effective 4 October 2022. - FY2022AdvancedAnnual report
「At a meeting of the board of directors held on 29 August 2022, the company resolved that アクティブメディカル would acquire all shares of ノアインターナショナル㈱ and make it a subsidiary, thereby making it an indirect subsidiary of the company.」
Under its policy of continuing M&A, the company resolved that アクティブメディカル would acquire all shares of ノアインターナショナル and presented 4 October 2022 as the scheduled business combination date. - FY2022-Q2RestatedAnnual report
「During the second quarter, the company conducted an absorption-type merger in which its consolidated subsidiary アクティブメディカル was the surviving company and its consolidated subsidiaries オズ, イーバスメディカル㈱ and ディーセンス㈱ were absorbed companies, and changed the corporate name to ㈱アルバース.」
The company reconfirms that the reorganization of the 4 companies related to the cardiovascular field and the corporate name change were completed effective 1 October 2021. - FY2022-Q1AdvancedAnnual report
「At a meeting of the board of directors held on 17 September 2021, the company resolved to acquire all issued shares of 佐野器械株式会社 (hereinafter, "佐野器械") and make it a subsidiary. Based on this resolution, the company entered into a share transfer agreement dated 17 September 2021 and acquired all shares effective 1 October 2021.」
Under its policy of continuing M&A, the company acquired all shares of 佐野器械 effective 1 October 2021, expanding its business base in the Keiji region and the endoscopy field. - FY2021AdvancedAnnual report
「In the management integration of 4 medical equipment dealers specializing in the cardiovascular field within the Group, scheduled for October 2021, the company will also work to expand market share and business scale in that field by further strengthening sales capabilities, and improve profitability by consolidating operations.」
In addition to its policy of continuing M&A and alliances, the company presented the integration of 4 companies specializing in the cardiovascular field in October 2021 as a specific implementation plan. - FY2021-Q3AdvancedAnnual report
「At a meeting of the board of directors held on 20 April 2021, the company resolved that its consolidated subsidiary アクティブメディカル would absorb オズ, イーバスメディカル株式会社 and ディーセンス株式会社 in a merger. This is an absorption-type merger between wholly owned subsidiaries of the company, and its impact on consolidated net sales, operating income and ordinary income will be immaterial. Business combination date 1 October 2021 (scheduled)」
The company resolved to reorganize the Group by merging オズ, イーバスメディカル and ディーセンス into アクティブメディカル as the surviving company, with implementation scheduled for 1 October 2021. - FY2020RestatedAnnual report
「The company plans to continue promoting M&A and alliances to expand its business scale and acquire personnel.」
In addition to M&A, the company is also pursuing alliances, with expansion of business scale and acquisition of personnel serving as continuing growth drivers. - FY2020-Q3AdvancedAnnual report
「Following the acquisition of all shares of ㈱アクティブメディカル effective 31 March 2020, the Company included it in the scope of consolidation from the third quarter of the current fiscal year.」
Regarding アクティブメディカル, whose acquisition had been decided in the previous quarter, the company acquired all shares and made it a consolidated subsidiary. - FY2020-Q2AdvancedAnnual report
「At a meeting of the board of directors held on 19 December 2019, the company approved the acquisition of all issued shares of 株式会社アクティブメディカル from 株式会社アクティブ・ケア, and entered into a share transfer agreement with 株式会社アクティブ・ケア on 24 December 2019. The transaction followed a tender process held on 20 December 2019, in which the company was the successful bidder on 23 December 2019.」
Regarding アクティブメディカル, the process progressed through the successful bid, board approval and execution of the share transfer agreement. The acquisition was scheduled for February 2020, with the company planning to acquire 100.00% of the issued shares. - FY2020-Q1AdvancedAnnual report
「Following the acquisition of all shares of アイテックスメディカル㈱ by 栗原医療器械店㈱, a consolidated subsidiary of the company, effective 1 July 2019, the company included アイテックスメディカル㈱ in the scope of consolidation from the first quarter.」
栗原医療器械店 acquired all shares of アイテックスメディカル effective 1 July 2019, making it a consolidated subsidiary. - FY2019Disposal of an acquired subsidiaryAnnual report
「Because シバタインテック, the company's capital and business alliance partner, operates in Fukushima Prefecture as one of the leading medical equipment dealers in the Tohoku region, the company decided to transfer the shares so that ジオット could work to improve its performance under シバタインテック and the two companies could maximize synergies in sales, logistics and other areas.」
While continuing to pursue M&A as a growth driver, the company stated its policy of transferring consolidated subsidiary ジオット to its capital and business alliance partner in light of the competitive environment in Fukushima Prefecture. - FY2019-Q3WorsenedAnnual report
「Regarding ㈱ミタス, recent policy developments, including revisions to medical reimbursement rates, affected demand for large equipment in the Hokuriku region, and its performance has remained below the plan initially prepared. ディーセンス㈱ has also remained below its initial plan because the number of cases involving its main products has not increased. After carefully examining recoverability in light of the future performance trends of both companies, the entire unamortized balance of goodwill arising at the time of their acquisition, ¥1,092 million, was recognized as an impairment loss under extraordinary losses.」
The performance of ミタス and ディーセンス after the management integration fell below the initial plan, and the entire unamortized goodwill balance of ¥1,092 million at the time of acquisition was recognized as an impairment loss. - FY2019-Q2AdvancedAnnual report
「During the second quarter, ヴィッツジャパン㈱ ceased to exist as a result of an absorption-type merger in which ㈱オズ was the surviving company, and was therefore excluded from the scope of consolidation.」
Regarding ヴィッツジャパン, the process progressed from becoming a subsidiary to the implementation of an absorption-type merger by オズ. The disclosure also describes specific execution of the Group reorganization, including ミタス, ディーセンス and ネットワーク. - FY2019-Q1RestatedAnnual report
「During the first quarter of the fiscal year, the company acquired all shares of ㈱ミタス and ディーセンス㈱ and made them consolidated subsidiaries. ヴィッツジャパン㈱, which became an indirect subsidiary through the acquisition of its shares by ㈱オズ, a consolidated subsidiary of the company, was also included in the scope of consolidation.」
The company reconfirms the consolidation of ミタス, ディーセンス and ヴィッツジャパン as the consolidated results for the current quarter following the integration implemented in the previous fiscal year. - FY2018AdvancedAnnual report
「The company subsequently acquired the shares for cash on 1 July 2018 and conducted the share exchange on 2 July 2018.」
In addition to making ミタス and ディーセンス wholly owned subsidiaries, オズ made ヴィッツジャパン a subsidiary on 1 July 2018. The integration of ミタス and ディーセンス was completed, while ヴィッツジャパン was scheduled to be absorbed in a merger on 1 October 2018. - FY2018-Q3Change in the share exchange terms accompanying the share splitAnnual report
「As stated in the amendment to the disclosure titled "(Amendment) Partial Amendment to 'Notice Concerning the Acquisition of Shares of 株式会社ミタス (formerly 福井医療株式会社) and ディーセンス株式会社 and Their Consolidation as Wholly Owned Subsidiaries through a Share Acquisition and Simplified Share Exchange, and Change in Major Shareholders,'" disclosed on 20 February 2018, the company carried out a share split effective 1 April 2018 based on a resolution of the board of directors meeting held on 20 February 2018. As a result, the number of shares to be delivered under the share exchange agreement changed.」
The integration with ミタス and ディーセンス continued toward the share acquisition scheduled for 1 July 2018 and the share exchange scheduled for 2 July 2018. The number of shares scheduled to be delivered was changed as a result of the share split. - FY2018-Q2AdvancedAnnual report
「At a meeting of the board of directors held on 7 December 2017, the company resolved to acquire shares in 株式会社ミタス and subsequently conduct a simplified share exchange under which the company would become the wholly owning parent company and ミタス and ディーセンス株式会社 would become wholly owned subsidiaries, and entered into the share transfer agreement and share exchange agreement described below.」
The integration with ミタス and ディーセンス progressed from the basic agreement stage to the execution of the share transfer agreement and share exchange agreement. The share acquisition was scheduled for 1 July 2018, and the effective date of the share exchange was scheduled for 2 July 2018. - FY2018-Q1RestatedAnnual report
「This basic agreement is not legally binding with respect to the above-mentioned management integration. After discussions among the company, ミタス and ディーセンス, the parties plan to execute a separate, legally binding definitive agreement following resolutions by their boards of directors and other necessary procedures.」
The company reiterates the basic agreement aimed at making ミタス and ディーセンス wholly owned subsidiaries, along with the planned definitive agreement and share acquisition. No new completion event is stated. - FY2017AdvancedAnnual report
「As announced on 9 August 2017, the company is currently holding discussions aimed at integrating its management with ㈱ミタス and ㈱ディーセンス.」
The company signed a basic agreement on the integration of its management with ミタス and ディーセンス and presented a specific schedule involving due diligence, a definitive agreement and the acquisition of shares from April to July 2018. - FY2016First statedAnnual report
「Under these circumstances, the Group plans to pursue M&A as a management strategy.」
The Group positions industry consolidation, driven by healthcare-cost containment and joint purchasing, as a growth opportunity and M&A as a management strategy.